Cargando…

Unexpected Cardiotoxicity in Patients With HER2-Mutant NSCLC Treated With Trastuzumab Deruxtecan: A Case Report

Antibody-drug conjugates targeting receptor tyrosine-protein kinase erbB-2 (ERBB2, HER2) have emerged as promising targeted options for HER2-mutant NSCLC. Among antibody-drug conjugates targeting HER2, trastuzumab deruxtecan was found to have the most impressive efficacy and is a potential new stand...

Descripción completa

Detalles Bibliográficos
Autores principales:	Riudavets, Mariona, Azarine, Arshid, Smaali, Sondes, Kim, Young-Wouk, Thomas de Montpréville, Vincent, Grecea, Alina Miruna, Naltet, Charles, Gazzah, Annas, Planchard, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9719088/ https://www.ncbi.nlm.nih.gov/pubmed/36471682 http://dx.doi.org/10.1016/j.jtocrr.2022.100432

Ejemplares similares

Trastuzumab deruxtecan for breast cancer
Publicado: (2022)

Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations
por: Riudavets, M., et al.
Publicado: (2021)

Response of an HER2-Mutated NSCLC Patient to Trastuzumab Deruxtecan and Monitoring of Plasma ctDNA Levels by Liquid Biopsy
por: Falk, Markus, et al.
Publicado: (2023)

Trastuzumab deruxtecan for the treatment of patients with HER2-positive gastric cancer
por: Kotani, Daisuke, et al.
Publicado: (2021)

Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors
por: Indini, Alice, et al.
Publicado: (2021)

Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer
por: Yang, Jiangping, et al.
Publicado: (2022)

Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers
por: DiPeri, Timothy P., et al.
Publicado: (2023)

Impact of Intercurrent Introduction of Steroids on Clinical Outcomes in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients under Immune-Checkpoint Inhibitors (ICI)
por: De Giglio, Andrea, et al.
Publicado: (2020)

Safety of trastuzumab deruxtecan: A meta‐analysis and pharmacovigilance study
por: Guo, Zihan, et al.
Publicado: (2022)

Incidence of interstitial lung disease and cardiotoxicity with trastuzumab deruxtecan in breast cancer patients: a systematic review and single-arm meta-analysis
por: Soares, L.R., et al.
Publicado: (2023)

Discovery and development of trastuzumab deruxtecan and safety management for patients with HER2-positive gastric cancer
por: Shitara, Kohei, et al.
Publicado: (2021)

A Case of HER2 Mutated Colorectal Cancer Treated Successfully With Fam-Trastuzumab Deruxtecan
por: Reddy, Aswanth, et al.
Publicado: (2023)

Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan
por: Alder, Laura, et al.
Publicado: (2023)

Cost-effectiveness of trastuzumab deruxtecan for previously treated HER2-low advanced breast cancer
por: Shi, Demin, et al.
Publicado: (2023)

Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure
por: Antonarelli, G., et al.
Publicado: (2023)

Multifocal and pathologically-confirmed brain metastasis complete response to trastuzumab deruxtecan
por: Moss, Nelson S, et al.
Publicado: (2022)

Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer
por: Rugo, H.S., et al.
Publicado: (2022)

Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases
por: Kabraji, Sheheryar, et al.
Publicado: (2023)

Impacts of clinicopathological factors on efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer
por: Nakajima, Hiromichi, et al.
Publicado: (2022)

Population Pharmacokinetics of Trastuzumab Deruxtecan in Patients With HER2‐Positive Breast Cancer and Other Solid Tumors
por: Yin, Ophelia, et al.
Publicado: (2020)

Enhertu (Fam-trastuzumab-deruxtecan-nxki) – Revolutionizing treatment paradigm for HER2-Low breast cancer
por: Siddiqui, Tasmiyah, et al.
Publicado: (2022)

Correction: A Case of HER2 Mutated Colorectal Cancer Treated Successfully With Fam-Trastuzumab Deruxtecan
por: Reddy, Aswanth, et al.
Publicado: (2023)

Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial
por: Mosele, Fernanda, et al.
Publicado: (2023)

Trastuzumab deruxtecan: An antibody-drug conjugate embracing its destiny in breast cancer
por: Makhlin, Igor, et al.
Publicado: (2022)

Trastuzumab deruxtecan in recurrent uterine serous carcinoma resistant to trastuzmab based-chemotherapy
por: McNamara, Blair, et al.
Publicado: (2023)

Managing the Risk of Lung Toxicity with Trastuzumab Deruxtecan (T-DXd): A Canadian Perspective
por: Henning, Jan-Willem, et al.
Publicado: (2023)

Adverse Event Profile Differences between Trastuzumab Emtansine and Trastuzumab Deruxtecan: A Real-world, Pharmacovigilance Study
por: Liu, Fen, et al.
Publicado: (2023)

Evolving Treatment Landscape of HER2-mutant Non-Small Cell Lung Cancer: Trastuzumab Deruxtecan and Beyond
por: Vathiotis, Ioannis A., et al.
Publicado: (2023)

Economic Evaluation of Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer in the United States
por: Lang, Yitian, et al.
Publicado: (2022)

Dramatic Recovery of Vision after Trastuzumab Deruxtecan Treatment of HER2-Positive Breast Cancer with Pituitary Metastasis
por: Matsui, Chiaki, et al.
Publicado: (2023)

Profile of Trastuzumab Deruxtecan in the Management of Patients with HER2-Positive Unresectable or Metastatic Breast Cancer: An Evidence-Based Review
por: Linehan, Anna S, et al.
Publicado: (2021)

Spotlight on Trastuzumab Deruxtecan (DS-8201,T-DXd) for HER2 Mutation Positive Non-Small Cell Lung Cancer
por: Azar, Ibrahim, et al.
Publicado: (2021)

Dramatic Response to Trastuzumab Deruxtecan Rechallenge in a Patient with HER2-Positive Gastric Cancer: A Case Report
por: Ogata, Takatsugu, et al.
Publicado: (2022)

Pharmacokinetics, Safety, and Efficacy of Trastuzumab Deruxtecan with Concomitant Ritonavir or Itraconazole in Patients with HER2-Expressing Advanced Solid Tumors
por: Takahashi, Shunji, et al.
Publicado: (2021)

Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial
por: Bartsch, Rupert, et al.
Publicado: (2022)

Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial
por: Pérez-García, José Manuel, et al.
Publicado: (2022)

Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer
por: Yoshino, Takayuki, et al.
Publicado: (2023)

Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and/or leptomeningeal disease (ROSET-BM)
por: Niikura, Naoki, et al.
Publicado: (2023)

Two cases of trastuzumab deruxtecan‐induced interstitial lung disease in advanced breast cancer
por: Gocho, Kyoko, et al.
Publicado: (2022)

Successful Trastuzumab-Deruxtecan Rechallenge After Interstitial Lung Disease: A Case Report
por: de Weger, Vincent A., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_i771jkklatpd007crbhm2pm942